Review examines when children with thyroid cancer may need radioactive iodine
The analysis supports more individualized use, especially distinguishing lower-risk disease from cancer that has spread.
Moderate evidenceReviewSome caution advised
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
The review covered 37 studies published from 2000 through 2025, along with international guidance. It considered cancer outcomes such as remission, recurrence, survival, and treatment responses, as well as possible long-term harms of radioactive iodine.
The authors described a shift away from giving radioactive iodine routinely after surgery. They reported that children with differentiated thyroid cancer generally have disease-specific survival above 95% to 98%, including many who have extensive lymph-node disease or lung metastases, but they also emphasized that radioactive iodine can have lasting effects. The review concluded that treatment decisions should be individualized, although the review itself does not establish a single rule for every patient.
What the review examined
Researchers conducted a PICO-based narrative review of 37 studies published between 2000 and 2025. The included evidence involved people younger than 18 with differentiated thyroid carcinoma and covered pediatric patient groups, registry analyses, meta-analyses, and international guidelines. The review examined radioactive-iodine-related remission, recurrence, survival, biochemical or structural responses, and treatment-related toxicity. The abstract does not state the total number of patients across the included studies or describe a new patient cohort.
Key conclusions
The review reported that radioactive iodine appeared most beneficial for selected children with intermediate- or high-risk disease, particularly those with lung metastases that were iodine-avid, meaning they absorbed iodine. For children considered low risk, the reviewed evidence generally showed excellent outcomes after surgery alone and did not demonstrate a survival advantage from routine additional radioactive iodine.
Reported possible toxicities included salivary-gland dysfunction, reduced bone-marrow activity, effects on the reproductive glands, second primary cancers, and rare fatal pulmonary fibrosis. The authors noted that contemporary American Thyroid Association and European Thyroid Association recommendations, together with registry data, have moved away from routine use and toward risk-adapted decisions. Because this was a narrative review, these findings summarize prior research and do not prove that radioactive iodine itself caused or prevented any individual outcome.
Who this may apply to
The findings may apply to children and adolescents with differentiated thyroid cancer who have characteristics similar to those represented in the reviewed studies, including differences in risk level and whether disease has spread to the lungs. They do not necessarily apply to adults, other types of thyroid cancer, or patients whose disease characteristics differ from those in the evidence. Because this article summarizes existing studies rather than testing one treatment strategy directly, it cannot predict the outcome for an individual child.
The significance
The review addresses a difficult balance in pediatric thyroid cancer: many children have very high disease-specific survival, while radioactive iodine can expose them to possible long-term harm. Its findings may help explain why the potential value of the treatment differs according to disease characteristics rather than being the same for every child.
This article is not a new clinical trial and does not determine the appropriate care for a particular patient. Its conclusions are most relevant to discussions of how existing evidence and guidelines evaluate radioactive iodine in pediatric differentiated thyroid cancer.
Limitations & evidence assessment
This was a narrative review, not a new randomized trial or a clearly systematic review with a reported pooled analysis. The 37 included studies may have differed in patient characteristics, risk definitions, treatments, follow-up, and outcome measurements, and the abstract does not report the size or quality of each study. The review may therefore be affected by limitations or biases in the underlying evidence. The abstract also provides limited detail about how studies were selected and does not establish how often the reported long-term toxicities occurred or which patients experienced them.
Why this evidence level: This was a narrative review of 37 published studies, including patient studies, registry analyses, meta-analyses, and guidelines. It summarizes existing evidence rather than reporting a new randomized comparison, and the abstract does not provide enough detail to assess the quality or consistency of every included study.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
This review examines pancreatic cystic lesions, especially intraductal papillary mucinous neoplasms (IPMNs), and how imaging may help distinguish them from other cysts. It discusses signs associated with cancer arising from an IPMN and the possibility of a separate pancreatic cancer developing elsewhere in the pancreas. The article is a review, not a new study of a defined group of patients.
A cluster-randomized trial in India studied 1,507 adults with heart failure with reduced ejection fraction. Compared with usual care, a nurse-coordinated program supported by mobile health tools was associated with more days alive and out of the hospital and fewer deaths during two years of follow-up.
Researchers reviewed human reports on electroconvulsive therapy for catatonia associated with Down syndrome regression disorder. Across 27 patients from one five-person case series and 14 earlier studies, reported catatonia scores were lower after treatment, but the evidence came from small, uncontrolled reports and shows an association rather than proof of cause.
